Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin <10g/dL). Patients (n=29; 18 RBC-transfusion dependent) received 0.5 mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients respond...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Daver, Naval, Shastri, Aditi, Kadia, Tapan, Newberry, Kate, Pemmaraju, Naveen, Jabbour, Elias, Zhou, Linghsa, Pierce, Sherry, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4157096/
https://ncbi.nlm.nih.gov/pubmed/25047979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2014.06.015
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares